FMP

FMP

Enter

HJLI - enVVeno Medical Corp...

photo-url-https://images.financialmodelingprep.com/symbol/HJLI.png

enVVeno Medical Corporation

HJLI

NASDAQ

Inactive Equity

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.

10.38 USD

-0.21000004 (-2.02%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

443.89M

485.69M

557.42M

623.94M

724.14M

818.6M

925.38M

1.05B

1.18B

1.34B

Revenue %

-

9.42

14.77

11.93

16.06

13.04

13.04

13.04

13.04

Ebitda

141.94M

228.44M

259.48M

292.14M

-

282.22M

319.04M

360.65M

407.7M

460.88M

Ebitda %

31.98

47.03

46.55

46.82

-

34.48

34.48

34.48

34.48

Ebit

123.51M

208.4M

237.43M

269.95M

-21.68M

251.47M

284.27M

321.36M

363.28M

410.66M

Ebit %

27.82

42.91

42.59

43.27

-2.99

30.72

30.72

30.72

30.72

Depreciation

18.42M

20.04M

22.05M

22.19M

21.68M

30.75M

34.76M

39.3M

44.42M

50.22M

Depreciation %

4.15

4.13

3.96

3.56

2.99

3.76

3.76

3.76

3.76

EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep